Chronic lithium does not alter human myo-inositol or phosphomonoester concentrations as measured by 1H and 31P MRS

Biological Psychiatry

Volumn 40, Issue 4, 1996, Pages 235-246

  Silverstone, Peter H ^a,b   Hanstock, Christopher C ^a   Fabian, James ^a   Staab, Randy ^a   Allen, Peter S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Human volunteers; Lithium; Magnetic resonance spectroscopy; Myo inositol

Indexed keywords

CHOLINE; CREATINE PHOSPHATE; INOSITOL; LITHIUM;

ADULT; ARTICLE; BRAIN; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030586852     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00382-7     Document Type: Article

References (71)

1. Agam G, Shapiro J, Levine J, Stier S, Schieids C, Bersudsky Y, Belmaker RH (1993): Short-term lithium treatment does not reduce human CSF inositol levels. Lithium 4:267-269.
2. Allison JH, Stewart MA (1971): Reduced brain inositol in lithium-treated rats. Nature New Biol 233:267-268.
3. Allison JH, Blisner ME, Holland WH, Hipps PP, Sherman WR (1976): Increased brain myo-inositol 1-phosphate in lithium-treated rats. Biochem Biophys Res Commun 71:664-670.
4. American Psychiatric Association (1994): DSM-IV. Washington, DC: American Psychiatric Association.
5. Avissar S, Schrieber G, Danon A, Belmaker RH (1988): Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 31:440-442.
6. Bachelard H, Badar-Goffer R (1993): NMR spectroscopy in neurochemistry. J Neurochem 61:412-429.
7. Baraban JM, Worley PF, Snyder SH (1989): Second messenger systems and psychoactive drug action: Focus on the phosphoinositide system and lithium. Am J Psychiatry 146:1251-1260.
8. Barnaby RJ (1991): Mass assay for inositol 1-phosphate in rat brain by high-performance liquid chromatography and pulsed amperometric detection. Anal Biochem 199:75-80.
9. Berridge MJ, Downes CP, Hanley MR (1982): Lithium amplifies agonist-dependent phosphatidyl-inositol responses in brain and salivary glands. Biochem J 206:587-595.
10. Berridge MJ, Downes CP, Hanley MR (1989): Neural and developmental actions of lithium: A unifying hypothesis. Cell 59:411-419.
11. Casebolt TL, Jope RS (1987): Chronic lithium treatment reduces norepinephrine-stimulated inositol phospholipid hydrolysis in rat cortex. Eur J Pharmacol 140:245-246.
12. 1H NMR detection of cerebral myo-inositol. FEBS Lett 187:167-172.
13. Cerdan S, Hansen CA, Johanson R, Inubushi T, Williamson JR (1986): Nuclear magnetic resonance spectroscopic analysis of myo-inositol phosphates including inositol 1,3,4,5-tetrakisphosphate. J Biol Chem 261:14676-14680.
14. Deutsch SI, Stanley M, Banay-Schwartz M, Peselow ED, Virgilio J, Geisler S, Mohs RC (1981): The effect of lithium on rat brain and erythrocyte glycine levels. Eur J Pharmacol 75:75-76.
15. Ehrlich BE, Diamond JM, Kaye W, Ornitz EM, Gosenfeld L (1979): Lithium transport in erythrocytes from a pair of twins with manic disorder. Am J Psychiatry 136:1477-1488.
16. Elphick M, Taghavi Z, Powell T, Godfrey PP (1988): Alteration of inositol phospholipid metabolism in rat cortex by lithium but not carbamazepine. Eur J Pharmacol 156:411-414.
17. Fisher SK, Heacock AM, Agranoff BW (1992): Inositol lipids and signal transduction in the nervous system: An update. J Neurochem 58:18-38.
18. Frahm J, Michaelis T, Merboldt KD, Bruhn H, Gyngell ML, Hanicke W (1990): Improvements in localized proton NMR-spectroscopy of human brain - Water suppression, short echo times, and 1-ml resolution. J Magn Reson 90:464-473.
19. Gani D, Downes CP, Batty I, Bramham J (1993): Lithium and myo-inositol homeostasis. Biochem Biophys Acta 1177:253-269.
20. Hallcher LM, Sherman WR (1980): The effect of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 255:10896-10901.
21. 2+ in neurons. Neuroscience 46:251-273.
22. Hirvonen MR (1991): Cerebral lithium, inositol and inositol monophosphates. Pharmacol Toxicol 69:22-27.
23. Hirvonen MR, Savolainen K (1991): Lithium-induced decrease of brain inositol and increase of brain inositol-1-phosphate is transient. Neurochem Res 16:905-911.
24. Ishima Y, Fujimagari M, Masuzawa Y, Waku K (1993): Inositol 1,4,5-trisphosphate accumulation in brain of lithium treated rats. Lipids 28:577-581.
25. Jenkinson S, Patel N, Challiss RAJ, Nahorski SR (1991): Inhibition of muscarinic receptor-stimulated inositol polyphosphate accumulation by lithium in rat cerebral cortex and striatum. Br J Pharmacol 104:208P.
26. Jenkinson S, Patel N, Nahorski SR, Challis RAJ (1993): Comparative effects of lithium on the phosphoinositide cycle in rat cerebral cortex, hippocampus, and striatum. J Neurochem 61:1082-1090.
27. Jope RS, Williams MB (1994): Lithium and brain signal transduction systems. Biochem Pharmacol 47:429-441.
28. 31P-MRS. J Affective Disord 22:185-190.
29. 7Li magnetic resonance spectroscopy. J Affective Disord 27:53-59.
30. Kato T, Takahashi S, Shioiri T, Murashita J, Hamakawa H, Inubushi T (1994): Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affective Disord 31:125-133.
31. Kennedy ED, Challiss RAJ, Nahorski S (1989): Lithium reduces the accumulation of inositol polyphosphate second messengers following cholinergic stimulation of cerebral cortex slices. J Neurochem 53:1652-1655.
32. Kennedy ED, Challiss RAJ, Ragan CI, Nahorski SR (1990): Reduced inositol polyphosphate accumulation and inositol supply induced by lithium in stimulated cerebral cortex slices. Biochem J 267:781-786.
33. 31P-MRS study. Schizophr Res 5:134-142.
34. Kofman O, Belmaker RH (1993): Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 34:839-852.
35. Koopmans RA, Li DK, Zhu G, Allen PS, Penn A, Paty DW (1993): Magnetic resonance spectroscopy of multiple sclerosis: In-vivo detection of myelin breakdown products. Lancet 341:631-632.
36. + increases accumulation of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate in cholinergically stimulated brain cortex slices in guinea pig, mouse and rat. Biochem J 282:377-385.
37. Majerus PW, Connolly TM, Bansal VS, Inhorn RC, Ross TS, Lips DL (1988): Inositol phosphates: Synthesis and degradation. J Biol Chem 263:3051-3054.
38. Mauri MC, Percudani M, Regazzetti MG, Altamura AC (1990): Alternative prophylactic treatments to lithium in bipolar disorders. Clin Neuropharmacol 13:S90-S96.
39. Moats RA, Lien YH, Filippi D, Ross BD (1993): Decrease in cerebral inositols in rats and humans. Biochem J 295:15-18.
40. Murphy TH, Wright DD, Baraban JM (1992): Phosphoinositide turnover associated with synaptic transmission. J Neurochem 59:2336-2339.
41. Nahorski SR, Potter BVL (1989): Molecular recognition of inositol polyphosphates by introcellular receptors and metabolic enzymes. Trends Pharmacol Sci 10:139-144.
42. Nahorski SR, Ragan CI, Challiss RAJ (1991): Lithium and the phosphoinositide cycle: An example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol Sci 12:297-303.
43. Newman ME, Drummer D, Lerer B (1990): Single and combined effects of desimipramine and lithium on serotonergic receptor number and second messenger function in rat brain. J Pharmacol Exp Ther 252:826-831.
44. Newman ME, Shapira B, Lerer B (1991): Effects of lithium and desimipramine on second messenger responses in rat hippocampus: Relation to G protein effects. Neuropharmacology 30:1297-1301.
45. Ordidge RJ, Connelly A, Lohman JAB (1986): Image-selected in vivo spectroscopy (ISIS) - A new technique for spatially selective NMR spectroscopy. J Magn Reson 66:283-294.
46. Perry TL, Hansen S, Gandham SS (1981): Postmortem changes of amino acid compounds in human and rat brain. J Neurochem 36:406-410.
47. Plenge P, Mellerup ET, Norgaard T (1981): Functional and structural rat kidney changes caused by peroral or parentral lithium treatment. Acta Psychiatrica Scand 63:303-313.
48. Plenge P, Stensgard A, Jensen HV, Thomsen C, Mellerup ET, Henriksen O (1994): 24-Hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. Biol Psychiatry 36:511-516.
49. Preece NE, Gadian DG, Houseman J, Williams SR (1992): Lithium-induced modulation of cerebral inositol phosphate metabolism in the rat: A multinuclear magnetic resonance study in vivo. Lithium 3:287-297.
50. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VS, Voss CB, Johnson WE (1984): Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 41:1096-1104.
51. Renshaw PF, Wicklund S (1988): In vivo measurement of lithium in humans by magnetic resonance spectroscopy. Biol Psychiatry 23:465-475.
52. Renshaw PF, Summers JJ, Renshaw CE, Hines KG, Leigh JS (1986): Changes in the 31P-NMR spectra of cats receiving lithium chloride systematically. Biol Psychiatry 21:694-698.
53. 31P NMR spectroscopy of agonist-stimulated phosphatidylinositol metabolism in cat brain. Magn Reson Med 4:221-226.
54. 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. Nucl Magn Reson Biomed 4:59-63.
55. Ross B, Kreis R, Ernst T (1992): Clinical tools for the 90s: Magnetic resonance spectroscopy and metabolite imaging. Eur J Radiol 14:128-140.
56. Savolainen KM, Hirvonen MR, Tarhanen J, Nelson SR, Samson FE, Pazdernik TL (1990): Changes in cerebral inositol-1-phosphate concentrations in LiCl-treated rats: Regional and strain differences. Neurochem Res 15:541-545.
57. Sharma R, Venkatasubramanian PN, Bárány M, Davis JM (1992): Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 8:43-49.
58. Sherman WH (1989): Inositol homeostasis, lithium and diabetes. In Michell RH, Drummond AH, Downes CP (eds), Inositol Lipids in Cell Signalling. London: Academic Press, pp 39-79.
59. Sherman WR, Leavitt AL, Honchar MP, Hallcher LM, Phillips BE (1981): Evidence that lithium alters phosphoinositide metabolism: Chronic administration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the rat. J Neurochem 36:1947-1951.
60. Sherman WR, Munsell LY, Gish BG, Honchar MP (1985): Effects of systematically administered lithium on phosphoinositide metabolism in rat brain, kidney, and testis. J Neurochem 44:798-807.
61. Sillence DJ, Downes CP (1993): Subcellular distribution of agonist-stimulated phosphatidylinositol synthesis in 1321 N1 astrocytoma cells. Biochem J 290:381-387.
62. Silverstone PH, Grahame-Smith DG (1992): A review of the relationship between calcium channels and psychiatric disorders. J Psychopharmacol 6:462-482.
63. Silverstone T, Turner P (1990): Drugs and Psychiatry, 4th ed. London: Routledge Keegan Paul.
64. Stubbs EB, Agranoff BW (1993): Lithium enhances muscarinic receptor-stimulated CDP-diacylglycerol formation in inositol-depleted SK-N-SH neuroblastoma cells. J Neurochem 60:1292-1299.
65. Sun GY, Navidi M, Yoa FG, Lin TN, Orth OE, Stubbs EB, MacQuarrie RA (1992): Lithium effects on inositol phospholipids and inositol phosphates: Evaluation of an in vivo model for assessing polyphosphinositide turnover in brain. J Neurochem 58:290-297.
66. Swann AC, Koslow SH, Katz MM, Maas JW, Javaid J, Secunda S, Robins E (1987): Lithium carbonate treatment of mania: Cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Arch Gen Psychiatry 44:345-354.
67. 2+ channels. Trends Pharmacol Sci 12:349-354.
68. 3 pituitary cells. Mol Pharmacol 42:671-678.
69. Wajda IJ, Banay-Schwartz M, De-Guzman T, Manigault I (1983): Dietary lithium during development: Changes in amino acid levels, ionic content, and [3H] spiperone binding in the brains of rats. Neurochem Res 8:637-648.
70. Wood AJ, Goodwin GM (1987): A review of the biochemical and neuropharmacological actions of lithium. Psychol Med 17:579-600.
71. Zhu G, Gheorghiu D, Allen PS (1992): Motional degradation of metabolite signal strengths when using STEAM: A correction method. Nucl Magn Reson Biomed 5:209-211.